vulvovaginal candidiasis - HEALTHIES
Business Wire: Phase 2b Results of Viamet’s Oral VT-1161 for the Treatment of Recurrent Vulvovaginal Candidiasis Presented at IDSOG Annual Meeting Recurrent vulvovaginal candidiasis (RVVC) is defined as the occurrence of three or more episodes of vulvovaginal candidiasis within a 12-month period. RVVC is estimated to occur in 5% to 8% of women ... Phase 2b Results of Viamet’s Oral VT-1161 for the Treatment of Recurrent Vulvovaginal Candidiasis Presented at IDSOG Annual Meeting Business Wire: Mycovia Pharmaceuticals Announces Publication of Positive Phase 3 Data Evaluating VIVJOA™ (oteseconazole) Capsules in Patients with Recurrent Vulvovaginal Candidiasis (RVVC ...
Understanding the Context
Titled “Efficacy and Safety of Oteseconazole in Recurrent Vulvovaginal Candidiasis,” the article assessed Mycovia’s two global, randomized, double-blind, placebo-controlled Phase 3 VIOLET studies, ... Mycovia Pharmaceuticals Announces Publication of Positive Phase 3 Data Evaluating VIVJOA™ (oteseconazole) Capsules in Patients with Recurrent Vulvovaginal Candidiasis (RVVC ... Treatments available for vulvovaginal candidiasis, more commonly referred to as vaginal yeast infection, include antifungal drugs in intravenous and pill formulations. But fungi are developing ...
Image Gallery
Key Insights
The American Journal of Managed Care: FDA Approves First Drug for Recurrent Vulvovaginal Candidiasis The drug, oteseconazole, is an azole antifungal indicated to reduce the incidence of recurrent vulvovaginal candidiasis in females who are infertile or postmenopausal. The FDA recently approved the ... Mycovia Pharmaceuticals Inc. said new phase III data on its oral antifungal, oteseconazole, showed that 37 weeks after women with a history of recurrent vulvovaginal candidiasis received a dose of the ...